Qiagen NV (QGEN) reported quarterly earnings results on Wednesday, Apr-27-2016. The company reported $0.19 EPS for the quarter. Analysts had a consensus estimate of $0.19. The company posted revenue of $298.40 million in the period, compared to analysts expectations of $293.91 million. The company’s revenue was down -.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Qiagen NV. Shares were Reiterated by Barclays on Feb 3, 2016 to “Overweight” and Lowered the Price Target to $ 27 from a previous price target of $28 .
Qiagen NV closed down -0.19 points or -0.79% at $23.86 with 6,64,581 shares getting traded on Friday. Post opening the session at $23.98, the shares hit an intraday low of $23.79 and an intraday high of $24.01 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products as well as instruments that automate the use of these products for sample preparation analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data enabling scientists or clinicians to interpret results and decide on further action.